Adicet Bio Inc

ACET

Company Profile

  • Business description

    Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.

  • Contact

    131 Dartmouth Street
    3rd Floor
    BostonMA02116
    USA

    T: +1 650 503-9095

    E: [email protected]

    https://www.adicetbio.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    152

Stocks News & Analysis

stocks

Qantas earnings: Jetstar capitalising on weaker domestic competition

Qantas’ budget brand performing well, with segment earnings up 55%.
stocks

Nvidia Earnings: No signs of a slowdown in demand for AI chips

A selloff in Nvidia stock on the earnings news looks like a buying opportunity to us.
stocks

ASX results reaction: WiseTech, Woolies, Sigma and more

A round up of notable stories and reactions as ASX reporting season rolls on.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,243.009.000.10%
CAC 407,703.9058.70-0.76%
DAX 4023,902.21137.71-0.57%
Dow JONES (US)45,544.8892.02-0.20%
FTSE 1009,187.3429.48-0.32%
HKSE25,077.6278.800.32%
NASDAQ21,455.55249.61-1.15%
Nikkei 22542,718.47110.32-0.26%
NZX 50 Index12,930.7327.650.21%
S&P 5006,460.2641.60-0.64%
S&P/ASX 2008,973.104.100.05%
SSE Composite Index3,857.9314.330.37%

Market Movers